KSQ Therapeutics
Biotechnology company applying genome-scale CRISPR/Cas9 functional genomic screening to nominate therapeutic targets and develop oncology candidates, with programs in engineered autologous tumor-infiltrating lymphocytes (TIL) and small-molecule DNA damage response inhibitors. Core activities include large-scale in vivo and in vitro CRISPR screens, CRISPR-based engineering of autologous T cells for adoptive cell therapy, feeder-free clinical-scale TIL manufacturing, preclinical tumor-model testing, early-phase clinical development, regulatory interactions, and partnerships for process development and clinical manufacturing. The company maintains an external scientific advisory board and a board of directors with experience in immunology, cell therapy, manufacturing sciences, and finance.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
KSQ-001EX (SOCS1-inactivated engineered TIL)
Autologous engineered TIL therapy with CRISPR/Cas9-mediated inactivation of SOCS1, manufactured using an accelerated feeder-free process and evaluated in a Phase 1/2 trial for multiple solid tumors.
KSQ-004EX (Regnase-1 and SOCS1 dual-inactivated engineered TIL)
Autologous engineered TIL product with dual CRISPR/Cas9 inactivation of Regnase-1 and SOCS1, manufactured using an accelerated feeder-free process and cleared for Phase 1/2 study by regulatory authorities.
KSQ-4279 (USP1 inhibitor small molecule)
Small-molecule inhibitor targeting USP1, identified using targeted functional genomic approaches and evaluated preclinically and in early clinical studies, with a licensing collaboration for further development.
ExPRESS
A proprietary, next-generation process to manufacture single and multiplex CRISPR/Cas9-edited eTIL therapies from surgical resections and core biopsies.
KSQ-004EX
Lead engineered tumor-infiltrating lymphocyte (eTIL) program advancing toward clinical studies for the treatment of solid tumors.
KSQ-004
An autologous, dual-gene edited tumor-infiltrating lymphocyte (TIL) cell product wherein Cas9/sgRNAs targeting the Regnase-1 and SOCS1 genes are electroporated into TIL to enhance anti-tumor potency and persistence against solid tumors.
KSQ-001EX (SOCS1-inactivated engineered TIL)
Autologous engineered TIL therapy with CRISPR/Cas9-mediated inactivation of SOCS1, manufactured using an accelerated feeder-free process and evaluated in a Phase 1/2 trial for multiple solid tumors.
KSQ-004EX (Regnase-1 and SOCS1 dual-inactivated engineered TIL)
Autologous engineered TIL product with dual CRISPR/Cas9 inactivation of Regnase-1 and SOCS1, manufactured using an accelerated feeder-free process and cleared for Phase 1/2 study by regulatory authorities.
KSQ-4279 (USP1 inhibitor small molecule)
Small-molecule inhibitor targeting USP1, identified using targeted functional genomic approaches and evaluated preclinically and in early clinical studies, with a licensing collaboration for further development.
ExPRESS
A proprietary, next-generation process to manufacture single and multiplex CRISPR/Cas9-edited eTIL therapies from surgical resections and core biopsies.
KSQ-004EX
Lead engineered tumor-infiltrating lymphocyte (eTIL) program advancing toward clinical studies for the treatment of solid tumors.
KSQ-004
An autologous, dual-gene edited tumor-infiltrating lymphocyte (TIL) cell product wherein Cas9/sgRNAs targeting the Regnase-1 and SOCS1 genes are electroporated into TIL to enhance anti-tumor potency and persistence against solid tumors.
Services
Collaborative discovery programs and target identification using genome-scale CRISPR screening in cancer and immune models.
Third-party manufacturing partnerships for process development, scale-up, and clinical manufacturing of engineered TIL therapies.
Collaborative discovery programs and target identification using genome-scale CRISPR screening in cancer and immune models.
Third-party manufacturing partnerships for process development, scale-up, and clinical manufacturing of engineered TIL therapies.
Expertise Areas
- Functional genomics and target discovery
- CRISPR-based gene editing for cell therapies
- Adoptive cell therapy development and clinical translation
- Cell therapy manufacturing and CMC strategy
Key Technologies
- CRISPR/Cas9 gene editing
- Genome-scale functional CRISPR screening
- In vivo CRISPR screening
- Engineered tumor-infiltrating lymphocyte (TIL) therapies
News & Updates
Announcement that the first patient was dosed in the Phase 1/2 clinical study evaluating the dual-edited engineered TIL therapy.
Press release announcing regulatory clearance to initiate a Phase 1/2 clinical study of the dual-edited engineered TIL therapy.
Corporate announcement of appointment to CMO role.
Peer-reviewed article describing CRISPR screen-informed design of a SOCS1-edited TIL therapy.
Regulatory clearances to initiate Phase 1/2 clinical studies for engineered TIL candidates developed using CRISPR-based target discovery and gene editing.
Entered a worldwide license and collaboration agreement for development and commercialization of a USP1 inhibitor.
Announcement that the first patient was dosed in the Phase 1/2 clinical study evaluating the dual-edited engineered TIL therapy.
Press release announcing regulatory clearance to initiate a Phase 1/2 clinical study of the dual-edited engineered TIL therapy.
Corporate announcement of appointment to CMO role.
Peer-reviewed article describing CRISPR screen-informed design of a SOCS1-edited TIL therapy.
Regulatory clearances to initiate Phase 1/2 clinical studies for engineered TIL candidates developed using CRISPR-based target discovery and gene editing.
Entered a worldwide license and collaboration agreement for development and commercialization of a USP1 inhibitor.